CA2395403A1 - Acides nucleiques, proteines et anticorps - Google Patents
Acides nucleiques, proteines et anticorps Download PDFInfo
- Publication number
- CA2395403A1 CA2395403A1 CA002395403A CA2395403A CA2395403A1 CA 2395403 A1 CA2395403 A1 CA 2395403A1 CA 002395403 A CA002395403 A CA 002395403A CA 2395403 A CA2395403 A CA 2395403A CA 2395403 A1 CA2395403 A1 CA 2395403A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- polypeptide
- sequence
- human
- zap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 127
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 124
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 94
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 94
- 108091005461 Nucleic proteins Proteins 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 583
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 566
- 229920001184 polypeptide Polymers 0.000 claims abstract description 561
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 380
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 380
- 239000002157 polynucleotide Substances 0.000 claims abstract description 380
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 177
- 238000000034 method Methods 0.000 claims abstract description 117
- 239000013598 vector Substances 0.000 claims abstract description 40
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 239000012634 fragment Substances 0.000 claims description 148
- 239000002299 complementary DNA Substances 0.000 claims description 142
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 123
- 125000003729 nucleotide group Chemical group 0.000 claims description 110
- 239000002773 nucleotide Substances 0.000 claims description 106
- 150000001413 amino acids Chemical class 0.000 claims description 51
- 230000000694 effects Effects 0.000 claims description 36
- 230000027455 binding Effects 0.000 claims description 33
- 230000014509 gene expression Effects 0.000 claims description 31
- 238000012217 deletion Methods 0.000 claims description 29
- 230000037430 deletion Effects 0.000 claims description 29
- 230000004071 biological effect Effects 0.000 claims description 26
- 239000000047 product Substances 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 5
- 238000004166 bioassay Methods 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 230000001575 pathological effect Effects 0.000 claims 8
- 239000006228 supernatant Substances 0.000 claims 2
- 241000282414 Homo sapiens Species 0.000 abstract description 219
- 239000000203 mixture Substances 0.000 abstract description 16
- 239000000556 agonist Substances 0.000 abstract description 8
- 239000005557 antagonist Substances 0.000 abstract description 7
- 238000010188 recombinant method Methods 0.000 abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 abstract description 6
- 238000002405 diagnostic procedure Methods 0.000 abstract description 5
- 238000012216 screening Methods 0.000 abstract description 5
- 238000010189 synthetic method Methods 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 226
- 206010028980 Neoplasm Diseases 0.000 description 119
- 235000018102 proteins Nutrition 0.000 description 117
- 230000000295 complement effect Effects 0.000 description 75
- 235000001014 amino acid Nutrition 0.000 description 71
- 201000011510 cancer Diseases 0.000 description 64
- 229940024606 amino acid Drugs 0.000 description 55
- 241001319148 Pharmacis Species 0.000 description 52
- 108091028043 Nucleic acid sequence Proteins 0.000 description 50
- 210000001072 colon Anatomy 0.000 description 44
- 210000004556 brain Anatomy 0.000 description 43
- -1 allelic. variants Proteins 0.000 description 42
- 210000001519 tissue Anatomy 0.000 description 40
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 39
- 230000001605 fetal effect Effects 0.000 description 37
- 238000009396 hybridization Methods 0.000 description 36
- 229920001223 polyethylene glycol Polymers 0.000 description 35
- 239000002202 Polyethylene glycol Substances 0.000 description 33
- 210000001672 ovary Anatomy 0.000 description 31
- 108020004414 DNA Proteins 0.000 description 30
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 29
- 230000000890 antigenic effect Effects 0.000 description 29
- 210000002307 prostate Anatomy 0.000 description 28
- 238000006467 substitution reaction Methods 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 108020001507 fusion proteins Proteins 0.000 description 27
- 102000037865 fusion proteins Human genes 0.000 description 27
- 210000003734 kidney Anatomy 0.000 description 26
- 210000004185 liver Anatomy 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 210000001744 T-lymphocyte Anatomy 0.000 description 24
- 125000000539 amino acid group Chemical group 0.000 description 24
- 125000005647 linker group Chemical group 0.000 description 24
- 210000002216 heart Anatomy 0.000 description 22
- 210000004072 lung Anatomy 0.000 description 22
- 102000005962 receptors Human genes 0.000 description 22
- 108020003175 receptors Proteins 0.000 description 22
- 230000005714 functional activity Effects 0.000 description 21
- 210000000481 breast Anatomy 0.000 description 20
- 230000004048 modification Effects 0.000 description 20
- 238000012986 modification Methods 0.000 description 20
- 108700026244 Open Reading Frames Proteins 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 210000003719 b-lymphocyte Anatomy 0.000 description 18
- 239000003446 ligand Substances 0.000 description 18
- 230000002611 ovarian Effects 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 210000004899 c-terminal region Anatomy 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 230000002163 immunogen Effects 0.000 description 15
- 108091026890 Coding region Proteins 0.000 description 14
- 108060003951 Immunoglobulin Proteins 0.000 description 14
- 239000000427 antigen Substances 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 102000018358 immunoglobulin Human genes 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 14
- 201000009030 Carcinoma Diseases 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 230000002759 chromosomal effect Effects 0.000 description 13
- 208000029742 colonic neoplasm Diseases 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 13
- 210000000265 leukocyte Anatomy 0.000 description 13
- 210000001550 testis Anatomy 0.000 description 13
- 210000004907 gland Anatomy 0.000 description 12
- 210000003205 muscle Anatomy 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 210000002741 palatine tonsil Anatomy 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 206010006187 Breast cancer Diseases 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 102100028701 General vesicular transport factor p115 Human genes 0.000 description 10
- 101000767151 Homo sapiens General vesicular transport factor p115 Proteins 0.000 description 10
- 210000000601 blood cell Anatomy 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 10
- 210000001185 bone marrow Anatomy 0.000 description 10
- 210000001541 thymus gland Anatomy 0.000 description 10
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 9
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 208000009956 adenocarcinoma Diseases 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000005755 formation reaction Methods 0.000 description 9
- 210000001161 mammalian embryo Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 206010025323 Lymphomas Diseases 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 8
- 238000004590 computer program Methods 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 230000003511 endothelial effect Effects 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 8
- 210000002536 stromal cell Anatomy 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 210000002826 placenta Anatomy 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 230000021736 acetylation Effects 0.000 description 6
- 238000006640 acetylation reaction Methods 0.000 description 6
- 238000002399 angioplasty Methods 0.000 description 6
- HRURXKIZWNSHQB-UHFFFAOYSA-N bis(trifluoromethylsulfonyl)azanide;cobalt(2+) Chemical compound [Co+2].FC(F)(F)S(=O)(=O)[N-]S(=O)(=O)C(F)(F)F.FC(F)(F)S(=O)(=O)[N-]S(=O)(=O)C(F)(F)F HRURXKIZWNSHQB-UHFFFAOYSA-N 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 230000006320 pegylation Effects 0.000 description 6
- 230000000284 resting effect Effects 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 108010025188 Alcohol oxidase Proteins 0.000 description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 240000008042 Zea mays Species 0.000 description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 238000007385 chemical modification Methods 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 235000005822 corn Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 5
- 210000000867 larynx Anatomy 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000002969 morbid Effects 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 230000001323 posttranslational effect Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229910001868 water Inorganic materials 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 241000235058 Komagataella pastoris Species 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108091006006 PEGylated Proteins Proteins 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 101710086015 RNA ligase Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 230000001919 adrenal effect Effects 0.000 description 4
- 230000009435 amidation Effects 0.000 description 4
- 238000007112 amidation reaction Methods 0.000 description 4
- 230000002788 anti-peptide Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 210000000748 cardiovascular system Anatomy 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 230000002357 endometrial effect Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 210000002458 fetal heart Anatomy 0.000 description 4
- 230000022244 formylation Effects 0.000 description 4
- 238000006170 formylation reaction Methods 0.000 description 4
- 238000002873 global sequence alignment Methods 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 210000002751 lymph Anatomy 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 230000004853 protein function Effects 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 238000002864 sequence alignment Methods 0.000 description 4
- 238000010798 ubiquitination Methods 0.000 description 4
- 230000034512 ubiquitination Effects 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 108090000144 Human Proteins Proteins 0.000 description 3
- 102000003839 Human Proteins Human genes 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 241000235648 Pichia Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 208000035269 cancer or benign tumor Diseases 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 210000004013 groin Anatomy 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 238000002887 multiple sequence alignment Methods 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 210000001577 neostriatum Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 2
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 101100230428 Caenorhabditis elegans hil-5 gene Proteins 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 206010014418 Electrolyte imbalance Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 241000237988 Patellidae Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 description 2
- 102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 102400001051 Restin Human genes 0.000 description 2
- 102100040756 Rhodopsin Human genes 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 241000011102 Thera Species 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 238000007818 agglutination assay Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000010516 arginylation Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000003477 cochlea Anatomy 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 108010038764 cytoplasmic linker protein 170 Proteins 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 150000003278 haem Chemical group 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000026045 iodination Effects 0.000 description 2
- 238000006192 iodination reaction Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000007498 myristoylation Effects 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000003349 osteoarthritic effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000003254 palate Anatomy 0.000 description 2
- 201000005163 papillary serous adenocarcinoma Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229940080469 phosphocellulose Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000013823 prenylation Effects 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 229940043131 pyroglutamate Drugs 0.000 description 2
- 230000006340 racemization Effects 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000005227 renal system Anatomy 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 201000004595 synovitis Diseases 0.000 description 2
- 208000001608 teratocarcinoma Diseases 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- JPNBVWIRDQVGAC-UHFFFAOYSA-N (2-nitrophenyl) hydrogen carbonate Chemical compound OC(=O)OC1=CC=CC=C1[N+]([O-])=O JPNBVWIRDQVGAC-UHFFFAOYSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- QRYXYRQPMWQIDM-UHFFFAOYSA-N 3-benzoyl-3-(2,5-dioxopyrrol-1-yl)-1-hydroxypyrrolidine-2,5-dione Chemical compound O=C1N(O)C(=O)CC1(C(=O)C=1C=CC=CC=1)N1C(=O)C=CC1=O QRYXYRQPMWQIDM-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 206010059199 Anterior chamber cleavage syndrome Diseases 0.000 description 1
- 101710170230 Antimicrobial peptide 1 Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000288575 Astomaea Species 0.000 description 1
- 208000023095 Autosomal dominant epidermolytic ichthyosis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000010059 Axenfeld-Rieger syndrome Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010004265 Benign familial pemphigus Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- 101000824382 Brugia malayi Fatty-acid and retinol-binding protein 1 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108090000044 Complement Factor I Proteins 0.000 description 1
- 102100035431 Complement factor I Human genes 0.000 description 1
- 108700037009 Congenital atransferrinemia Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100285903 Drosophila melanogaster Hsc70-2 gene Proteins 0.000 description 1
- 101100178718 Drosophila melanogaster Hsc70-4 gene Proteins 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 102100040068 E3 ubiquitin-protein ligase TRIM37 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 206010014489 Elliptocytosis Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 201000009040 Epidermolytic Hyperkeratosis Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108700000224 Familial apoceruloplasmin deficiency Proteins 0.000 description 1
- 208000037574 Familial benign chronic pemphigus Diseases 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 208000027655 Hailey-Hailey disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 230000010556 Heparin Binding Activity Effects 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 101000610400 Homo sapiens E3 ubiquitin-protein ligase TRIM37 Proteins 0.000 description 1
- 101000918657 Homo sapiens L-xylulose reductase Proteins 0.000 description 1
- 101001038006 Homo sapiens Lysophosphatidic acid receptor 3 Proteins 0.000 description 1
- 101000584785 Homo sapiens Ras-related protein Rab-7a Proteins 0.000 description 1
- 101000611338 Homo sapiens Rhodopsin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000037862 Ion Transporter Human genes 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241001523179 Lasia <small-headed fly> Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 102100040388 Lysophosphatidic acid receptor 3 Human genes 0.000 description 1
- 208000027933 Mannosidase Deficiency disease Diseases 0.000 description 1
- 201000008643 Meckel syndrome Diseases 0.000 description 1
- 102100030550 Menin Human genes 0.000 description 1
- 101710169972 Menin Proteins 0.000 description 1
- 201000002983 Mobius syndrome Diseases 0.000 description 1
- 208000034167 Moebius syndrome Diseases 0.000 description 1
- ZOKXTWBITQBERF-AKLPVKDBSA-N Molybdenum Mo-99 Chemical compound [99Mo] ZOKXTWBITQBERF-AKLPVKDBSA-N 0.000 description 1
- 201000006054 Mulibrey nanism Diseases 0.000 description 1
- 208000000592 Nasal Polyps Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 208000005265 Neonatal severe primary hyperparathyroidism Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 101150050917 PNS1 gene Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241001503951 Phoma Species 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 239000000381 Placental Lactogen Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 102100030019 Ras-related protein Rab-7a Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 241001582326 Renia Species 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108050007496 Shikimate kinase 2 Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 206010040741 Sinus bradycardia Diseases 0.000 description 1
- 108700017375 Specific Granule Deficiency Proteins 0.000 description 1
- 206010041509 Spherocytic anaemia Diseases 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 206010052483 Spur cell anaemia Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042432 Sucrose intolerance Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042778 Syndactyly Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000003757 Tricho-dento-osseous syndrome Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 208000014769 Usher Syndromes Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 206010072666 White sponge naevus Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 101150099430 accD5 gene Proteins 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 206010001323 adrenal adenoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 206010001689 alkaptonuria Diseases 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 208000002304 ankyrin-B-related cardiac arrhythmia Diseases 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 201000007867 atransferrinemia Diseases 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 210000003588 centroblast Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000003200 chromosome mapping Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 108700033817 due to Aceruloplasminemia Systemic Hemosiderosis Proteins 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 208000033286 epidermolytic ichthyosis Diseases 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 210000001280 germinal center Anatomy 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000001722 hereditary mucosal leukokeratosis Diseases 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000002302 hypocalciuric effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000003017 in situ immunoassay Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 201000008633 iridogoniodysgenesis syndrome Diseases 0.000 description 1
- 208000014384 isolated congenital growth hormone deficiency Diseases 0.000 description 1
- 201000002022 isolated growth hormone deficiency Diseases 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000000231 kidney cortex Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000003246 kidney medulla Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000003659 long QT syndrome 4 Diseases 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000016055 micropapillary serous carcinoma Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 208000020066 ovarian serous surface papillary adenocarcinoma Diseases 0.000 description 1
- 201000003031 ovary papillary carcinoma Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 101150036991 pccB gene Proteins 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 208000003068 pituitary dwarfism Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 108010039177 polyphenylalanine Proteins 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108010078347 pregnancy-associated murine protein 1 Proteins 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 201000004012 propionic acidemia Diseases 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000013197 protein A assay Methods 0.000 description 1
- 208000007750 pseudohypoaldosteronism Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 201000010384 renal tubular acidosis Diseases 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 208000006891 retinitis pigmentosa 17 Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 102220278881 rs749263651 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000002416 scanning tunnelling spectroscopy Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000035527 susceptibility to 2 malignant hyperthermia Diseases 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000014990 symphalangism Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 210000000538 tail Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 208000011317 telomere syndrome Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 208000017613 trichodontoosseous syndrome Diseases 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000002396 uvula Anatomy 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention concerne de protéines, plus précisément, des molécules isolées d'acide nucléique codant de nouveaux polypeptides. Elle concerne de nouveaux polypeptides et des anticorps qui lient ces polypeptides, ainsi que des vecteurs, des cellules hôtes, et des procédés de recombinaison et de synthèse destinés à produire des polynucléotides humains et/ou des polypeptides et des anticorps. L'invention concerne également des procédés de diagnostic et thérapeutiques servant à diagnostiquer, à traiter, à prévenir et/ou à pronostiquer des troubles relatifs à ces nouveaux polypeptides. Elle concerne en outre des procédés de criblage destinés à identifier des agonistes et antagonistes desdits polynucléotides et polypeptides. Elle concerne enfin des procédés et/ou des compositions conçus pour inhiber ou renforcer la production et la fonction desdits polypeptides.
Applications Claiming Priority (235)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17906500P | 2000-01-31 | 2000-01-31 | |
US60/179,065 | 2000-01-31 | ||
US18062800P | 2000-02-04 | 2000-02-04 | |
US60/180,628 | 2000-02-04 | ||
US18466400P | 2000-02-24 | 2000-02-24 | |
US60/184,664 | 2000-02-24 | ||
US18635000P | 2000-03-02 | 2000-03-02 | |
US60/186,350 | 2000-03-02 | ||
US18987400P | 2000-03-16 | 2000-03-16 | |
US60/189,874 | 2000-03-16 | ||
US19007600P | 2000-03-17 | 2000-03-17 | |
US60/190,076 | 2000-03-17 | ||
US19812300P | 2000-04-18 | 2000-04-18 | |
US60/198,123 | 2000-04-18 | ||
US20551500P | 2000-05-19 | 2000-05-19 | |
US60/205,515 | 2000-05-19 | ||
US20946700P | 2000-06-07 | 2000-06-07 | |
US60/209,467 | 2000-06-07 | ||
US21488600P | 2000-06-28 | 2000-06-28 | |
US60/214,886 | 2000-06-28 | ||
US21513500P | 2000-06-30 | 2000-06-30 | |
US60/215,135 | 2000-06-30 | ||
US21688000P | 2000-07-07 | 2000-07-07 | |
US21664700P | 2000-07-07 | 2000-07-07 | |
US60/216,880 | 2000-07-07 | ||
US60/216,647 | 2000-07-07 | ||
US21749600P | 2000-07-11 | 2000-07-11 | |
US21748700P | 2000-07-11 | 2000-07-11 | |
US60/217,487 | 2000-07-11 | ||
US60/217,496 | 2000-07-11 | ||
US21829000P | 2000-07-14 | 2000-07-14 | |
US60/218,290 | 2000-07-14 | ||
US22096400P | 2000-07-26 | 2000-07-26 | |
US22096300P | 2000-07-26 | 2000-07-26 | |
US60/220,963 | 2000-07-26 | ||
US60/220,964 | 2000-07-26 | ||
US22575700P | 2000-08-14 | 2000-08-14 | |
US22451800P | 2000-08-14 | 2000-08-14 | |
US22575800P | 2000-08-14 | 2000-08-14 | |
US22451900P | 2000-08-14 | 2000-08-14 | |
US22526700P | 2000-08-14 | 2000-08-14 | |
US22527000P | 2000-08-14 | 2000-08-14 | |
US22521400P | 2000-08-14 | 2000-08-14 | |
US22575900P | 2000-08-14 | 2000-08-14 | |
US22544700P | 2000-08-14 | 2000-08-14 | |
US22521300P | 2000-08-14 | 2000-08-14 | |
US22526600P | 2000-08-14 | 2000-08-14 | |
US22526800P | 2000-08-14 | 2000-08-14 | |
US60/225,267 | 2000-08-14 | ||
US60/225,213 | 2000-08-14 | ||
US60/225,268 | 2000-08-14 | ||
US60/224,518 | 2000-08-14 | ||
US60/225,266 | 2000-08-14 | ||
US60/225,447 | 2000-08-14 | ||
US60/224,519 | 2000-08-14 | ||
US60/225,270 | 2000-08-14 | ||
US60/225,759 | 2000-08-14 | ||
US60/225,214 | 2000-08-14 | ||
US60/225,758 | 2000-08-14 | ||
US60/225,757 | 2000-08-14 | ||
US22627900P | 2000-08-18 | 2000-08-18 | |
US60/226,279 | 2000-08-18 | ||
US22686800P | 2000-08-22 | 2000-08-22 | |
US22718200P | 2000-08-22 | 2000-08-22 | |
US22668100P | 2000-08-22 | 2000-08-22 | |
US60/226,681 | 2000-08-22 | ||
US60/227,182 | 2000-08-22 | ||
US60/226,868 | 2000-08-22 | ||
US22700900P | 2000-08-23 | 2000-08-23 | |
US60/227,009 | 2000-08-23 | ||
US22892400P | 2000-08-30 | 2000-08-30 | |
US60/228,924 | 2000-08-30 | ||
US22934300P | 2000-09-01 | 2000-09-01 | |
US22928700P | 2000-09-01 | 2000-09-01 | |
US22934500P | 2000-09-01 | 2000-09-01 | |
US22934400P | 2000-09-01 | 2000-09-01 | |
US60/229,287 | 2000-09-01 | ||
US60/229,343 | 2000-09-01 | ||
US60/229,345 | 2000-09-01 | ||
US60/229,344 | 2000-09-01 | ||
US22951300P | 2000-09-05 | 2000-09-05 | |
US22950900P | 2000-09-05 | 2000-09-05 | |
US60/229,513 | 2000-09-05 | ||
US60/229,509 | 2000-09-05 | ||
US23043700P | 2000-09-06 | 2000-09-06 | |
US23043800P | 2000-09-06 | 2000-09-06 | |
US60/230,437 | 2000-09-06 | ||
US60/230,438 | 2000-09-06 | ||
US23124400P | 2000-09-08 | 2000-09-08 | |
US23124300P | 2000-09-08 | 2000-09-08 | |
US23141300P | 2000-09-08 | 2000-09-08 | |
US23124200P | 2000-09-08 | 2000-09-08 | |
US23208100P | 2000-09-08 | 2000-09-08 | |
US23208000P | 2000-09-08 | 2000-09-08 | |
US23141400P | 2000-09-08 | 2000-09-08 | |
US60/231,244 | 2000-09-08 | ||
US60/231,413 | 2000-09-08 | ||
US60/232,080 | 2000-09-08 | ||
US60/231,414 | 2000-09-08 | ||
US60/231,242 | 2000-09-08 | ||
US60/231,243 | 2000-09-08 | ||
US60/232,081 | 2000-09-08 | ||
US23196800P | 2000-09-12 | 2000-09-12 | |
US60/231,968 | 2000-09-12 | ||
US23239700P | 2000-09-14 | 2000-09-14 | |
US23240000P | 2000-09-14 | 2000-09-14 | |
US23240100P | 2000-09-14 | 2000-09-14 | |
US23239800P | 2000-09-14 | 2000-09-14 | |
US23306500P | 2000-09-14 | 2000-09-14 | |
US23306400P | 2000-09-14 | 2000-09-14 | |
US23306300P | 2000-09-14 | 2000-09-14 | |
US23239900P | 2000-09-14 | 2000-09-14 | |
US60/232,400 | 2000-09-14 | ||
US60/233,064 | 2000-09-14 | ||
US60/232,397 | 2000-09-14 | ||
US60/232,401 | 2000-09-14 | ||
US60/232,399 | 2000-09-14 | ||
US60/232,398 | 2000-09-14 | ||
US60/233,065 | 2000-09-14 | ||
US60/233,063 | 2000-09-14 | ||
US23427400P | 2000-09-21 | 2000-09-21 | |
US23422300P | 2000-09-21 | 2000-09-21 | |
US60/234,223 | 2000-09-21 | ||
US60/234,274 | 2000-09-21 | ||
US23499700P | 2000-09-25 | 2000-09-25 | |
US23499800P | 2000-09-25 | 2000-09-25 | |
US60/234,998 | 2000-09-25 | ||
US60/234,997 | 2000-09-25 | ||
US23548400P | 2000-09-26 | 2000-09-26 | |
US60/235,484 | 2000-09-26 | ||
US23583600P | 2000-09-27 | 2000-09-27 | |
US23583400P | 2000-09-27 | 2000-09-27 | |
US60/235,836 | 2000-09-27 | ||
US60/235,834 | 2000-09-27 | ||
US23636700P | 2000-09-29 | 2000-09-29 | |
US23636800P | 2000-09-29 | 2000-09-29 | |
US23637000P | 2000-09-29 | 2000-09-29 | |
US23632700P | 2000-09-29 | 2000-09-29 | |
US23636900P | 2000-09-29 | 2000-09-29 | |
US60/236,367 | 2000-09-29 | ||
US60/236,327 | 2000-09-29 | ||
US60/236,368 | 2000-09-29 | ||
US60/236,370 | 2000-09-29 | ||
US60/236,369 | 2000-09-29 | ||
US23703800P | 2000-10-02 | 2000-10-02 | |
US23680200P | 2000-10-02 | 2000-10-02 | |
US23703700P | 2000-10-02 | 2000-10-02 | |
US23704000P | 2000-10-02 | 2000-10-02 | |
US23703900P | 2000-10-02 | 2000-10-02 | |
US60/237,038 | 2000-10-02 | ||
US60/237,040 | 2000-10-02 | ||
US60/237,037 | 2000-10-02 | ||
US60/237,039 | 2000-10-02 | ||
US60/236,802 | 2000-10-02 | ||
US23993500P | 2000-10-13 | 2000-10-13 | |
US23993700P | 2000-10-13 | 2000-10-13 | |
US60/239,937 | 2000-10-13 | ||
US60/239,935 | 2000-10-13 | ||
US24122100P | 2000-10-20 | 2000-10-20 | |
US24182600P | 2000-10-20 | 2000-10-20 | |
US24180900P | 2000-10-20 | 2000-10-20 | |
US24178500P | 2000-10-20 | 2000-10-20 | |
US24180800P | 2000-10-20 | 2000-10-20 | |
US24178700P | 2000-10-20 | 2000-10-20 | |
US24178600P | 2000-10-20 | 2000-10-20 | |
US24096000P | 2000-10-20 | 2000-10-20 | |
US60/241,809 | 2000-10-20 | ||
US60/241,786 | 2000-10-20 | ||
US60/241,808 | 2000-10-20 | ||
US60/241,826 | 2000-10-20 | ||
US60/241,785 | 2000-10-20 | ||
US60/241,221 | 2000-10-20 | ||
US60/240,960 | 2000-10-20 | ||
US60/241,787 | 2000-10-20 | ||
US24461700P | 2000-11-01 | 2000-11-01 | |
US60/244,617 | 2000-11-01 | ||
US24652600P | 2000-11-08 | 2000-11-08 | |
US24652500P | 2000-11-08 | 2000-11-08 | |
US24652700P | 2000-11-08 | 2000-11-08 | |
US24647600P | 2000-11-08 | 2000-11-08 | |
US24661100P | 2000-11-08 | 2000-11-08 | |
US24647500P | 2000-11-08 | 2000-11-08 | |
US24647400P | 2000-11-08 | 2000-11-08 | |
US24652800P | 2000-11-08 | 2000-11-08 | |
US24647700P | 2000-11-08 | 2000-11-08 | |
US24661000P | 2000-11-08 | 2000-11-08 | |
US24653200P | 2000-11-08 | 2000-11-08 | |
US60/246,525 | 2000-11-08 | ||
US60/246,475 | 2000-11-08 | ||
US60/246,526 | 2000-11-08 | ||
US60/246,609 | 2000-11-08 | ||
US60/246,474 | 2000-11-08 | ||
US60/246,611 | 2000-11-08 | ||
US60/246,527 | 2000-11-08 | ||
US60/246,613 | 2000-11-08 | ||
US60/246,478 | 2000-11-08 | ||
US60/246,477 | 2000-11-08 | ||
US60/246,476 | 2000-11-08 | ||
US60/246,532 | 2000-11-08 | ||
US60/246,528 | 2000-11-08 | ||
US60/246,610 | 2000-11-08 | ||
US60/246,524 | 2000-11-08 | ||
US60/246,523 | 2000-11-08 | ||
US60/249,211 | 2000-11-17 | ||
US60/249,244 | 2000-11-17 | ||
US60/249,212 | 2000-11-17 | ||
US60/249,214 | 2000-11-17 | ||
US60/249,265 | 2000-11-17 | ||
US60/249,213 | 2000-11-17 | ||
US60/249,217 | 2000-11-17 | ||
US60/249,264 | 2000-11-17 | ||
US60/249,216 | 2000-11-17 | ||
US60/249,208 | 2000-11-17 | ||
US60/249,245 | 2000-11-17 | ||
US60/249,207 | 2000-11-17 | ||
US60/249,300 | 2000-11-17 | ||
US60/249,299 | 2000-11-17 | ||
US60/249,218 | 2000-11-17 | ||
US60/249,215 | 2000-11-17 | ||
US60/249,297 | 2000-11-17 | ||
US60/249,209 | 2000-11-17 | ||
US60/249,210 | 2000-11-17 | ||
US60/250,160 | 2000-12-01 | ||
US60/250,391 | 2000-12-01 | ||
US60/251,988 | 2000-12-05 | ||
US60/251,030 | 2000-12-05 | ||
US60/256,719 | 2000-12-05 | ||
US60/251,479 | 2000-12-06 | ||
US60/251,869 | 2000-12-08 | ||
US60/251,856 | 2000-12-08 | ||
US60/251,990 | 2000-12-08 | ||
US60/251,989 | 2000-12-08 | ||
US60/251,868 | 2000-12-08 | ||
US60/254,097 | 2000-12-11 | ||
US60/259,678 | 2001-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2395403A1 true CA2395403A1 (fr) | 2001-08-02 |
Family
ID=27587117
Family Applications (37)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002395666A Withdrawn CA2395666A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395729A Pending CA2395729A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395699A Pending CA2395699A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002394039A Abandoned CA2394039A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395827A Withdrawn CA2395827A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395734A Withdrawn CA2395734A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002398877A Withdrawn CA2398877A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392438A Abandoned CA2392438A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395787A Withdrawn CA2395787A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002397407A Withdrawn CA2397407A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002393912A Withdrawn CA2393912A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395403A Withdrawn CA2395403A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395654A Withdrawn CA2395654A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395885A Withdrawn CA2395885A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002398411A Withdrawn CA2398411A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395849A Pending CA2395849A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395872A Withdrawn CA2395872A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395693A Pending CA2395693A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392751A Abandoned CA2392751A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395858A Withdrawn CA2395858A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002393652A Withdrawn CA2393652A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392398A Abandoned CA2392398A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002397839A Withdrawn CA2397839A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395295A Withdrawn CA2395295A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395671A Withdrawn CA2395671A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395738A Withdrawn CA2395738A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002393618A Abandoned CA2393618A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392428A Abandoned CA2392428A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395398A Withdrawn CA2395398A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines, et anticorps |
CA002395178A Withdrawn CA2395178A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392422A Abandoned CA2392422A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392450A Abandoned CA2392450A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395724A Pending CA2395724A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002393002A Withdrawn CA2393002A1 (fr) | 2000-01-31 | 2001-01-17 | Acides ncleiques, proteines et anticorps |
CA002394841A Withdrawn CA2394841A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392757A Abandoned CA2392757A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395816A Withdrawn CA2395816A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
Family Applications Before (11)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002395666A Withdrawn CA2395666A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395729A Pending CA2395729A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395699A Pending CA2395699A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002394039A Abandoned CA2394039A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395827A Withdrawn CA2395827A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395734A Withdrawn CA2395734A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002398877A Withdrawn CA2398877A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392438A Abandoned CA2392438A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395787A Withdrawn CA2395787A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002397407A Withdrawn CA2397407A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002393912A Withdrawn CA2393912A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
Family Applications After (25)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002395654A Withdrawn CA2395654A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395885A Withdrawn CA2395885A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002398411A Withdrawn CA2398411A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395849A Pending CA2395849A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395872A Withdrawn CA2395872A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395693A Pending CA2395693A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392751A Abandoned CA2392751A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395858A Withdrawn CA2395858A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002393652A Withdrawn CA2393652A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392398A Abandoned CA2392398A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002397839A Withdrawn CA2397839A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395295A Withdrawn CA2395295A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395671A Withdrawn CA2395671A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395738A Withdrawn CA2395738A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002393618A Abandoned CA2393618A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392428A Abandoned CA2392428A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395398A Withdrawn CA2395398A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines, et anticorps |
CA002395178A Withdrawn CA2395178A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392422A Abandoned CA2392422A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392450A Abandoned CA2392450A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395724A Pending CA2395724A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002393002A Withdrawn CA2393002A1 (fr) | 2000-01-31 | 2001-01-17 | Acides ncleiques, proteines et anticorps |
CA002394841A Withdrawn CA2394841A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002392757A Abandoned CA2392757A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
CA002395816A Withdrawn CA2395816A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
Country Status (3)
Country | Link |
---|---|
AU (16) | AU2001241409A1 (fr) |
CA (37) | CA2395666A1 (fr) |
WO (48) | WO2001055355A1 (fr) |
Families Citing this family (271)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002008288A2 (fr) * | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides |
US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7579160B2 (en) | 1998-03-18 | 2009-08-25 | Corixa Corporation | Methods for the detection of cervical cancer |
US6960570B2 (en) | 1998-03-18 | 2005-11-01 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US7258860B2 (en) | 1998-03-18 | 2007-08-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US6706262B1 (en) | 1998-03-18 | 2004-03-16 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
CA2328496C (fr) | 1998-05-15 | 2016-01-05 | Genentech, Inc. | Polypeptides homologues de il-17 et utilisations therapeutiques de ceux-ci |
US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
US6929938B2 (en) | 2001-08-15 | 2005-08-16 | Millennium Pharmaceuticals, Inc. | 25501, a human transferase family member and uses therefor |
WO2000050565A2 (fr) * | 1999-02-25 | 2000-08-31 | Thomas Jefferson University | Compositions, kits et procedes concernant le gene fez1 de l'homme, nouveau gene suppresseur des tumeurs |
US7141417B1 (en) | 1999-02-25 | 2006-11-28 | Thomas Jefferson University | Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene |
EP1157038A4 (fr) * | 1999-02-26 | 2005-01-19 | Smithkline Beecham Corp | Clonage du recepteur 7tm (axor 17) du type p2y |
WO2000056881A1 (fr) * | 1999-03-23 | 2000-09-28 | Human Genome Sciences, Inc. | 48 proteines humaines secretees |
CA2365601A1 (fr) | 1999-03-29 | 2000-10-05 | Kansai Technology Licensing Organization Co., Ltd. | Nouvelle cytidine desaminase |
EP1637541B1 (fr) * | 1999-09-01 | 2010-03-03 | Genentech, Inc. | Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci |
US20020151047A1 (en) * | 2001-01-08 | 2002-10-17 | Yi Hu | Novel human protease and polynucleotides encoding the same |
AU1238201A (en) * | 1999-10-27 | 2001-05-08 | Millennium Pharmaceuticals, Inc. | Novel molecules and the card-related protein family and uses thereof |
US6893818B1 (en) | 1999-10-28 | 2005-05-17 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
US7005499B1 (en) * | 1999-11-18 | 2006-02-28 | Genentech, Inc. | Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same |
EP1878795A3 (fr) * | 1999-11-30 | 2008-01-23 | Genentech, Inc. | Compositions et procédés pour le traitement de maladies liées au système immunitaire |
EP1250426A2 (fr) * | 1999-12-01 | 2002-10-23 | Genentech Inc. | Polypeptides transmembranaires et secretes et les acides nucleiques codant ceux-ci |
CN1300781A (zh) * | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | 一种新的多肽-人shc蛋白43和编码这种多肽的多核苷酸 |
US20040043397A1 (en) | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
AU2001237973B2 (en) | 2000-01-26 | 2006-09-07 | Agensys, Inc. | 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer |
US6953682B2 (en) | 2000-02-10 | 2005-10-11 | Millennium Pharmaceuticals, Inc. | Nucleic acid sequences encoding adenylate kinase, phospholipid scramblase-like, DNA fragmentation factor-like, phosphatidylserine synthase-like, and atpase-like molecules and uses therefor |
US7078205B2 (en) | 2000-02-17 | 2006-07-18 | Millennium Pharmaceuticals, Inc. | Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, atpase molecules, acyltransferase molecules, pyridoxal-phosphate dependent enzyme molecules and uses therefor |
US20020082212A1 (en) * | 2000-07-20 | 2002-06-27 | Millennium Pharmaceuticals, Inc. | 7716, a novel human ATPase and uses therefor |
US20020090705A1 (en) * | 2000-07-14 | 2002-07-11 | Rachel Meyers | 62088, a novel human nucleoside phosphatase family member and uses thereof |
US20020055159A1 (en) * | 2000-06-15 | 2002-05-09 | Meyers Rachel A. | 23680,a novel human aminotransferase and uses therefor |
US7718397B2 (en) | 2000-03-21 | 2010-05-18 | Genentech, Inc. | Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof |
AU2001250980A1 (en) * | 2000-03-23 | 2001-10-03 | Carmela Beger | Brca-1 regulators and methods of use |
AU2001245974A1 (en) | 2000-03-24 | 2001-10-08 | Millennium Pharmaceuticals, Inc. | 3714, 16742, 23546, and 13887 novel protein kinase molecules and uses therefor |
US20030198953A1 (en) * | 2000-03-30 | 2003-10-23 | Spytek Kimberly A. | Novel proteins and nucleic acids encoding same |
US7632929B2 (en) | 2000-04-20 | 2009-12-15 | The Board Of Trustees Of The University Of Arkansas | Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof |
JP2004511205A (ja) | 2000-04-25 | 2004-04-15 | レキシコン・ジェネティクス・インコーポレーテッド | 新規ヒトキナーゼプロテインおよびそれをコードするポリヌクレオチド |
AU2001257407A1 (en) * | 2000-04-26 | 2001-11-07 | Millennium Pharmaceuticals, Inc. | 21657, a human short-chain dehydrogenase and uses thereof |
US6808876B1 (en) * | 2000-05-02 | 2004-10-26 | Immusol, Inc. | Cellular regulators of infectious agents and methods of use |
WO2001085921A2 (fr) * | 2000-05-12 | 2001-11-15 | Merck Patent Gmbh | Nouvelle serine-threonine kinase-4 |
EP1158001B1 (fr) * | 2000-05-26 | 2007-11-14 | F. Hoffmann-La Roche Ag | Un acide nucléique produit excessivement dans des cellules tumorales humaines, une protéine codée par ledit acide nucléique et un procédé de diagnose de tumeurs |
AU7634301A (en) * | 2000-05-26 | 2001-12-03 | Bayer Aktiengesellschaft | Regulation of human p78-like serine/threonine kinase |
DE10027170A1 (de) * | 2000-05-31 | 2001-12-13 | Schering Ag | Humanes PEM als Target für die Fertilitätskontrolle |
US7098311B2 (en) * | 2000-06-02 | 2006-08-29 | Brigham And Women's Hospital | Fusion of jAZF1 and jjAZ1 genes in endometrial stromal tumors |
US20030096969A1 (en) | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU6531101A (en) * | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU6604901A (en) * | 2000-06-05 | 2001-12-17 | Bayer Aktiengesellschaft | Regulation of human hm74-like g protein coupled receptor |
US6323016B1 (en) | 2000-06-09 | 2001-11-27 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
EP1287029A2 (fr) * | 2000-06-09 | 2003-03-05 | Corixa Corporation | Compositions et procedes pour la therapie et le diagnostic du cancer du colon |
WO2001096546A2 (fr) * | 2000-06-16 | 2001-12-20 | Incyte Genomics, Inc. | Proteine-phosphatases |
EP2075253A1 (fr) * | 2000-06-23 | 2009-07-01 | Genentech, Inc. | Méthodes et composés pour la diagnose et le traitement de troubles associés à l'angiogenèse |
WO2002000861A2 (fr) * | 2000-06-26 | 2002-01-03 | Millennium Pharmaceuticals, Inc. | 46619, une nouvelle synthase beta-cetoacyle et utilisations de cette derniere |
AU2001270215A1 (en) * | 2000-06-27 | 2002-01-08 | Curagen Corporation | Novel polynucleotides and polypeptides encoded thereby |
US7094587B2 (en) | 2000-06-27 | 2006-08-22 | Millennium Pharmaceuticals, Inc. | 16002 Molecules and uses therefor |
US6774223B2 (en) | 2000-06-28 | 2004-08-10 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
WO2002002761A2 (fr) * | 2000-06-30 | 2002-01-10 | Millennium Pharmaceuticals, Inc. | 57658, nouvelle uridine kinase humaine et utilisations correspondantes |
AU2001271843A1 (en) * | 2000-07-07 | 2002-01-21 | Incyte Genomics, Inc. | Gtp-binding proteins |
AU2001273239A1 (en) * | 2000-07-07 | 2002-01-21 | Incyte Genomics, Inc. | Transporters and ion channels |
EP1303620A2 (fr) * | 2000-07-18 | 2003-04-23 | Bayer Aktiengesellschaft | Regulation de protease a serine humaine de type desc1 |
US6740751B2 (en) | 2000-07-18 | 2004-05-25 | Board Of Regents, The University Of Texas System | Methods and compositions for stabilizing microtubules and intermediate filaments in striated muscle cells |
AU8762901A (en) * | 2000-07-25 | 2002-02-05 | Merck Patent Gmbh | Novel protein containing ring finger domaine r1p4 |
AU2001277202A1 (en) * | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Bstp-ras/rerg protein and related reagents and methods of use thereof |
AU2001277200A1 (en) * | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Bstp-cad protein and related reagents and methods of use thereof |
EP1657254A3 (fr) * | 2000-08-01 | 2006-06-07 | Genentech, Inc. | Polypeptide, acides nucléiques le codant, et leur utilisation pour le diagnostic du cancer |
US7335732B2 (en) | 2000-08-01 | 2008-02-26 | Genentech, Inc. | PRO9799 polypeptides |
EP1315431A1 (fr) * | 2000-08-02 | 2003-06-04 | Millennium Pharmaceuticals, Inc. | Membre de la famille du facteur de liberation du gtp humain (15368) et ses utilisations |
WO2002010217A2 (fr) | 2000-08-02 | 2002-02-07 | The Johns Hopkins University | Profils d'expression de cellules endotheliales |
WO2002012330A2 (fr) * | 2000-08-04 | 2002-02-14 | Zymogenetics, Inc. | Zzp1, proteine humaine secretee |
US6943245B2 (en) | 2000-08-10 | 2005-09-13 | Board Of Regents, The University Of Texas System | Tumor suppressor CAR-1 |
JP2004506422A (ja) * | 2000-08-11 | 2004-03-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 新規マイトジェン活性化キナーゼ |
EP1326985A1 (fr) * | 2000-08-18 | 2003-07-16 | MERCK PATENT GmbH | Identification d'un gene d'acetyltransferase n-terminale humaine |
US6706513B2 (en) | 2000-08-21 | 2004-03-16 | Bristol-Myers Squibb Company | Adenosine deaminase homolog |
JP2004519217A (ja) * | 2000-08-21 | 2004-07-02 | インサイト・ゲノミックス・インコーポレイテッド | 微小管関連タンパク質およびチューブリン |
WO2002016579A2 (fr) * | 2000-08-24 | 2002-02-28 | Eli Lilly And Company | Acides nucleiques, vecteurs, cellules hotes, polypeptides et utilisations de ces derniers |
CA2705366A1 (fr) * | 2000-08-28 | 2002-03-07 | Agensys, Inc. | Acide nucleique et proteine correspondante denommes 85p1b3 utilises dans le traitement et la detection de cancers |
CA2420902A1 (fr) * | 2000-08-28 | 2002-03-07 | Craig A. Rosen | 18 proteines humaines secretees |
AU2001284176A1 (en) * | 2000-08-28 | 2002-03-13 | Astrazeneca Ab | Molecules involved in the regulation of insulin in resistance syndrome (irs) |
AU2002210464A1 (en) * | 2000-08-30 | 2002-03-13 | Bayer Aktiengesellschaft | Regulation of human aminotransferase-like enzyme |
WO2002018577A2 (fr) * | 2000-08-30 | 2002-03-07 | Millennium Pharmaceuticals, Inc. | Nouveau facteur de terminaison du gtp humain 48921 et ses utilisations |
WO2002018552A2 (fr) * | 2000-08-30 | 2002-03-07 | Bayer Aktiengesellschaft | Regulation d'enzyme humaine de type aminotransferase |
AU2001286714A1 (en) * | 2000-08-30 | 2002-03-13 | Millennium Pharmaceuticals, Inc. | 54370, a novel human sulfate transporter and uses therefor |
WO2002018582A2 (fr) * | 2000-08-31 | 2002-03-07 | Millennium Pharmaceuticals, Inc. | 62112, nouvelle deshydrogenase humaine et ses utilisations |
US7153669B2 (en) | 2000-09-05 | 2006-12-26 | Amgen Inc. | Nucleic acids encoding MK61 receptors |
CA2421265A1 (fr) * | 2000-09-05 | 2002-03-14 | Incyte Genomics, Inc. | Molecules utilisees a des fins diagnostiques et therapeutiques |
US20020142464A1 (en) * | 2000-09-08 | 2002-10-03 | Millennium Pharmaceuticals, Inc. | 38646, a novel guanine nucleotide exchange factor and uses therefor |
US6372468B1 (en) * | 2000-09-14 | 2002-04-16 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
US6391606B1 (en) * | 2000-09-14 | 2002-05-21 | Pe Corporation | Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof |
US20040048245A1 (en) * | 2000-10-05 | 2004-03-11 | Shimkets Richard A. | Novel human proteins, polynucleotides encoding them and methods of using the same |
WO2002031126A2 (fr) * | 2000-10-11 | 2002-04-18 | Bayer Aktiengesellschaft | Regulation d'une peptidyl-prolyl cis-trans isomerase de type cyclophiline humaine |
WO2002031132A2 (fr) * | 2000-10-11 | 2002-04-18 | Millennium Pharmaceuticals, Inc. | Nouvel element de la famille des phosphatases humaines a double specificite, appele 8843, et utilisation de ce dernier |
US20020064831A1 (en) * | 2000-10-12 | 2002-05-30 | The Texas A&M University System | Nucleic acid sequences encoding CMG proteins, CMG proteins, and methods for their use |
EP1474528A4 (fr) * | 2000-10-13 | 2006-06-14 | Protein Design Labs Inc | Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate |
US6531297B2 (en) * | 2000-10-20 | 2003-03-11 | Applera Corporation | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
WO2002062945A2 (fr) | 2000-10-25 | 2002-08-15 | Diadexus, Inc. | Compositions et techniques relatives a des genes et a des proteines specifiques du poumon |
WO2002036781A2 (fr) * | 2000-10-31 | 2002-05-10 | Bayer Aktiengesellschaft | Regulation de la glutathione-s-transferase humaine |
WO2002038743A2 (fr) * | 2000-11-09 | 2002-05-16 | Glaxo Group Limited | Enzyme |
EP1349934A2 (fr) | 2000-11-20 | 2003-10-08 | Diadexus, Inc. | Compositions et methodes relatives a des genes et des proteines specifiques aux seins |
AU2001297765A1 (en) * | 2000-12-05 | 2002-10-21 | Incyte Genomics, Inc. | Ligases |
US7776523B2 (en) | 2000-12-07 | 2010-08-17 | Novartis Vaccines And Diagnostics, Inc. | Endogenous retroviruses up-regulated in prostate cancer |
EP1339845A2 (fr) | 2000-12-07 | 2003-09-03 | ZymoGenetics, Inc. | Proteine associee au complement adipocyte zacrp3x2 |
WO2002048328A2 (fr) * | 2000-12-14 | 2002-06-20 | Pe Corporation (Ny) | Proteines kinases humaines isolees, molecules d'acide nucleique codant des proteines kinases humaines et utilisations associees |
US20020142376A1 (en) * | 2000-12-20 | 2002-10-03 | Gennady Merkulov | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
IL155687A0 (en) | 2000-12-22 | 2003-11-23 | Bristol Myers Squibb Co | Polynucleotides encoding hlrrsi1 polypeptides |
US7892730B2 (en) | 2000-12-22 | 2011-02-22 | Sagres Discovery, Inc. | Compositions and methods for cancer |
US6423521B1 (en) | 2000-12-28 | 2002-07-23 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
WO2002053591A1 (fr) * | 2000-12-30 | 2002-07-11 | Lion Bioscience Ag | Cofacteur de recepteur nucleaire mammalien cf12 et ses procedes d'utilisation |
US20030219739A1 (en) * | 2001-01-30 | 2003-11-27 | Glass David J. | Novel nucleic acid and polypeptide molecules |
WO2002098917A2 (fr) * | 2001-02-12 | 2002-12-12 | Curagen Corporation | Proteines, polynucleotides codant pour lesdites proteines et methodes d'utilisation desdites proteines |
EP1637601A3 (fr) * | 2001-02-21 | 2006-03-29 | Curagen Corporation | Protéines , polynucléotides codant pour ces protéines et procédés d'utilisation |
US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
AU2002250143A1 (en) * | 2001-03-16 | 2002-10-03 | Eli Lilly And Company | Lp mammalian proteins; related reagents |
US6913904B2 (en) * | 2001-03-27 | 2005-07-05 | Applera Corporation | Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof |
AU2002258626B2 (en) | 2001-04-10 | 2007-01-18 | Agensys, Inc. | Nucleid acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer |
EP2280030A3 (fr) | 2001-04-10 | 2011-06-15 | Agensys, Inc. | Acides nucléiques et protéines correspondantes utiles dans la détection et le traitement des différents cancers |
EP1573022B1 (fr) | 2001-04-10 | 2011-06-08 | Agensys, Inc. | Acide nucleique et proteine correspondante intitulee 184p1e2, utilises dans le traitement et la detection de cancers |
WO2002086113A2 (fr) * | 2001-04-24 | 2002-10-31 | Isis Innovation Ltd | Enzyme et marqueur snp pour le depistage d'une maladie |
JPWO2002088175A1 (ja) * | 2001-04-24 | 2004-08-19 | 大塚製薬株式会社 | クローン病抗体結合性ペプチド及びクローン病の検査方法 |
KR100882762B1 (ko) | 2001-05-07 | 2009-02-09 | 시오노기세이야쿠가부시키가이샤 | 혈관신생 마커로서 사용되는 폴리펩티드 및 이의 dna |
AU2002314048A1 (en) * | 2001-05-09 | 2002-11-18 | Bayer Aktiengesellschaft | Regulation of human phosphatidic acid phosphatase type 2c-like protein |
US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
US7235358B2 (en) * | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
WO2003000901A2 (fr) * | 2001-06-26 | 2003-01-03 | Decode Genetics Ehf. | Acides nucleiques codant des proteines kinases |
US20030120040A1 (en) | 2001-06-29 | 2003-06-26 | Genentech, Inc. | Secreted and Transmembrane polypeptides and nucleic acids encoding the same |
GB2399086A (en) * | 2001-08-02 | 2004-09-08 | Aeomica Inc | Human zinc finger containing gene MDZ4 |
WO2003031568A2 (fr) * | 2001-08-17 | 2003-04-17 | Incyte Genomics, Inc. | Molecules de signalisation intracellulaire |
US7270960B2 (en) | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
WO2003023063A1 (fr) * | 2001-09-07 | 2003-03-20 | Sankyo Company, Limited | Methode d'estimation du risque d'apparition de diabetes |
WO2003025175A2 (fr) * | 2001-09-17 | 2003-03-27 | Molecular Engines Laboratories | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments |
WO2003040369A2 (fr) * | 2001-09-17 | 2003-05-15 | Molecular Engines Laboratories | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments |
CA2417455C (fr) | 2001-09-28 | 2008-01-29 | Brigham Young University | Variants nouveaux de la cyclooxygenase et methodes d'utilisation |
WO2003038087A1 (fr) | 2001-10-04 | 2003-05-08 | Kansai Technology Licensing Organization Co., Ltd. | Promoteur du gene dr5 et promoteur du gene siah-1 |
US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
WO2003031607A1 (fr) * | 2001-10-10 | 2003-04-17 | Bayer Healthcare Ag | Regulation de deshydrogenase/reductase des chaines courtes humaine |
DE60220621T2 (de) | 2001-11-09 | 2008-03-06 | Proteologics, Inc. | Posh Nukleinsäure, Polypeptide und darauf bezogene Verfahren |
AU2002365162A1 (en) | 2001-11-14 | 2003-07-09 | Northwestern University | Self-assembly and mineralization of peptide-amphiphile nanofibers |
CA2468145A1 (fr) * | 2001-11-21 | 2003-05-30 | Japan Science And Technology Agency | Facteurs de transcription de gene de la choree de huntington |
US7151162B2 (en) | 2001-12-06 | 2006-12-19 | The University Of Children's Hospital Of Both Cantons Of Basel | Nuclear protein |
AU2002339697A1 (en) * | 2001-12-19 | 2003-06-30 | Genset S.A. | Gmg-5 polynucleotides and polypeptides and uses thereof |
JP2003245084A (ja) * | 2001-12-20 | 2003-09-02 | Morinaga Milk Ind Co Ltd | 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途 |
DE10163467A1 (de) * | 2001-12-21 | 2003-11-27 | Axaron Bioscience Ag | Protein 24B2 und zugrundliegende DNA-Sequenz |
US6759222B2 (en) | 2002-01-02 | 2004-07-06 | Millennium Pharmaceuticals, Inc. | 14815, a human kinase family member and uses therefor |
WO2003057870A1 (fr) * | 2002-01-07 | 2003-07-17 | Bayer Healthcare Ag | Proteine humaine analogue a la phosphatase de l'acide phosphatidique de type 2 |
AU2003235631A1 (en) * | 2002-01-15 | 2003-07-30 | Bayer Aktiengesellschaft | Human subtilisin/kexin-like convertase |
AU2003205611A1 (en) * | 2002-01-15 | 2003-07-30 | Medigene Ag | Dilated cardiomyopathy associated gene-2 (dcmag-2): a cytoplasmatic inducer of sarcomeric remodeling in cardiomyocytes |
WO2003062429A1 (fr) * | 2002-01-23 | 2003-07-31 | Yamanouchi Pharmaceutical Co., Ltd. | Nouvelle serine protease |
US7371719B2 (en) | 2002-02-15 | 2008-05-13 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
EP1338609A1 (fr) * | 2002-02-21 | 2003-08-27 | MEMOREC Stoffel GmbH-Medizinisch-Molekulare Entwicklung, Köln | Un outre récepteur KDR et son utilisation |
CA2478271A1 (fr) * | 2002-03-05 | 2003-09-18 | Applera Corporation | Proteines transporteuses humaines isolees, molecules d'acide nucleique codant celles-ci, et utilisations associees |
GB2388113A (en) * | 2002-03-06 | 2003-11-05 | Oxford Glycosciences | B-cell malignancy-associated protein |
DK1918386T3 (da) | 2002-03-13 | 2012-01-02 | Genomic Health Inc | Genekspressionsprofiler i biopsier af tumorvæv |
AU2003220913A1 (en) * | 2002-03-19 | 2003-09-29 | Tanabe Seiyaku Co., Ltd. | Novel g protein-coupled recepotrs and genes thereof |
US7527935B2 (en) | 2002-03-19 | 2009-05-05 | Mitsubishi Tanabe Pharma Corporation | G-protein coupled receptor having eicosanoid as ligand and gene thereof |
GB0206684D0 (en) * | 2002-03-21 | 2002-05-01 | Babraham Inst | Novel proteins |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
US7329502B2 (en) | 2002-04-25 | 2008-02-12 | The United States Of America As Represented By The Department Of Health And Human Services | ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) |
JP2004041003A (ja) * | 2002-05-17 | 2004-02-12 | Takeda Chem Ind Ltd | 新規タンパク質、そのdnaおよびその用途 |
EP2275118A3 (fr) | 2002-05-29 | 2011-10-19 | DeveloGen Aktiengesellschaft | Proteines specifiques du pancreas |
AU2003237367A1 (en) | 2002-06-03 | 2003-12-19 | Chiron Corporation | Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer |
DK1513934T3 (da) | 2002-06-06 | 2011-05-02 | Oncotherapy Science Inc | Gener og polypeptider relateret til humane coloncancersygdomme |
JP2005535308A (ja) | 2002-06-13 | 2005-11-24 | カイロン コーポレイション | Hml−2ポリペプチド発現用ベクター |
AU2003281626A1 (en) * | 2002-07-22 | 2004-02-09 | Masayoshi Harigai | Novel gene associated with rheumatoid arthritis |
JP4186004B2 (ja) | 2002-08-14 | 2008-11-26 | 独立行政法人産業技術総合研究所 | 新規n−アセチルガラクトサミン転移酵素およびそれをコードする核酸 |
AU2003243151A1 (en) * | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
WO2004018518A1 (fr) * | 2002-08-23 | 2004-03-04 | Japan Science And Technology Agency | Peptides antigeniques de tumeur cancereuse solide humains, polynucleotides codant pour ceux-ci et utilisation de ceux-ci |
AU2003250989A1 (en) * | 2002-08-27 | 2004-03-19 | Epigenomics Ag | Method and nucleic acids for the analysis of breast cell proliferative disorders |
US7452969B2 (en) | 2002-08-30 | 2008-11-18 | Licentia Ltd | Neurotrophic factor protein and uses thereof |
CN1703524B (zh) * | 2002-09-30 | 2010-04-07 | 肿瘤疗法科学股份有限公司 | 与人胰腺癌相关的基因和多肽 |
EP1552310A2 (fr) * | 2002-10-17 | 2005-07-13 | EVOTEC Neurosciences GmbH | L'utilisation de la proteine et du gene de la nicotinamide mononucleotide adenylyltransferase 2 (nmnat-2) pour le diagnostique et la therapie des maladies neurodegeneratives |
AU2002952216A0 (en) * | 2002-10-23 | 2002-11-07 | The Walter And Eliza Hall Institute Of Medical Research | Novel therapeutic molecules |
US7554021B2 (en) | 2002-11-12 | 2009-06-30 | Northwestern University | Composition and method for self-assembly and mineralization of peptide amphiphiles |
EP1570080A4 (fr) | 2002-11-15 | 2006-03-01 | Genomic Health Inc | Etablissement de profils d'expressions genetique du cancer a recepteur de facteur de croissance epidermique positif |
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
AU2002953341A0 (en) * | 2002-12-13 | 2003-01-09 | The Walter And Eliza Hall Institute Of Medical Research | A novel phosphoprotein |
AU2003287764B2 (en) * | 2002-12-13 | 2010-01-21 | The Walter And Eliza Hall Institute Of Medical Research | A novel phosphoprotein |
US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
WO2004070025A2 (fr) * | 2003-02-05 | 2004-08-19 | Juan Saus | Nouvelles isoformes de la proteine liant l'antigene de goodpasture et troubles induits par une proteine incorrectement repliee |
EP1445614A1 (fr) * | 2003-02-06 | 2004-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Méthodes d'évaluation in vitro de l'état de progression d'un virus HIV chez un individu |
US7074891B2 (en) * | 2003-02-07 | 2006-07-11 | Posco | Leukocyte stimulating peptides |
AU2004213871B9 (en) | 2003-02-20 | 2009-09-03 | Genomic Health, Inc. | Use of intronic RNA to measure gene expression |
WO2004078784A1 (fr) * | 2003-03-04 | 2004-09-16 | Astellas Pharma Inc. | Nouveau gene associe a des conditions fibreuses |
PL378582A1 (pl) | 2003-03-19 | 2006-05-02 | Biogen Idec Ma Inc. | Białko wiążące receptor Nogo |
ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
EP3470535B1 (fr) | 2003-06-24 | 2020-04-01 | Genomic Health, Inc. | Prédiction de probabilité de récurrence de cancer |
US7526387B2 (en) | 2003-07-10 | 2009-04-28 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
ATE528397T1 (de) | 2003-08-08 | 2011-10-15 | Perseus Proteomics Inc | Bei krebs überexprimiertes gen |
US20050136434A1 (en) * | 2003-08-12 | 2005-06-23 | Mai Xu | Isolated heat-inducible cell surface protein and hyperthermia-based tumor immunotargeting therapy |
US20070178458A1 (en) * | 2003-09-05 | 2007-08-02 | O'brien Philippa | Methods of diagnosis and prognosis of ovarian cancer II |
TW200517503A (en) * | 2003-09-10 | 2005-06-01 | Japan Science & Tech Agency | Group of genes differentially expressed in peripheral blood cells and diagnostic method and assay method using the same |
EP1667712B1 (fr) * | 2003-10-02 | 2010-07-21 | GlaxoSmithKline Biologicals S.A. | Antigenes de b. pertussis et leur utilisation dans la vaccination |
CA2541006C (fr) | 2003-10-03 | 2015-02-17 | Brigham And Women's Hospital | Ligands de tim-3 et methodes associees |
WO2005040791A2 (fr) * | 2003-10-21 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics et therapeutiques pour maladies liees au recepteur de peptides similaire a la somatostatine et a l'angiogenine (salpr) |
US20050255560A1 (en) * | 2003-11-21 | 2005-11-17 | Zeren Gao | Ztnf11, a tumor necrosis factor |
CA2549164A1 (fr) | 2003-12-05 | 2005-06-23 | Northwestern University | Amphiphiles peptidiques a assemblage automatique et procedes associes d'administration de facteur de croissance |
JP4718490B2 (ja) | 2003-12-23 | 2011-07-06 | ジェノミック ヘルス, インコーポレイテッド | フラグメント化rnaの全般的増幅 |
US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
PT3556866T (pt) | 2004-03-02 | 2021-04-30 | Univ Johns Hopkins | Mutações do gene de pik3ca em cancros humanos |
TW200539890A (en) | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
WO2005090569A1 (fr) * | 2004-03-24 | 2005-09-29 | The Council Of The Queensland Institute Of Medical Research | Cancer et acides nucleiques et proteines de testicule vsm1 et vsm2, et leurs utilisations |
WO2005095450A2 (fr) | 2004-03-30 | 2005-10-13 | Nsgene A/S | Utilisation therapeutique d'un facteur de croissance, nsg33 |
DK2163650T3 (en) | 2004-04-09 | 2015-11-02 | Genomic Health Inc | Genekspressionsmarkører for prediction of response to chemotherapy |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
WO2005118832A2 (fr) * | 2004-06-01 | 2005-12-15 | Bayer Healthcare Ag | Agents diagnostiques et therapeutiques pour des maladies associees a une proteine de type kinase regulee par serum/glucocorticoide (sgkl) |
AU2005258335B2 (en) | 2004-06-24 | 2011-03-17 | Biogen Ma Inc. | Treatment of conditions involving demyelination |
US7587279B2 (en) | 2004-07-06 | 2009-09-08 | Genomic Health | Method for quantitative PCR data analysis system (QDAS) |
US7985831B2 (en) * | 2004-08-05 | 2011-07-26 | Toagosei Co., Ltd. | Crohn's disease antibody epitope peptide and reagent for testing Crohn's disease |
HUE051605T2 (hu) | 2004-11-05 | 2021-03-01 | Nsabp Found Inc | Kemoterápiára adott válasz elõrejelzése génexpressziós markereket alkalmazva |
CA2585561C (fr) | 2004-11-05 | 2018-07-17 | Genomic Health, Inc. | Resultat de groupe esr1, pgr, bcl2 et scube2 comme indicateurs de pronostic de cancer du sein et de prediction de la reponse au traitement |
EP2845865A1 (fr) | 2004-11-12 | 2015-03-11 | Xencor Inc. | Variantes Fc avec liaison altérée en FcRn |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
CA2598251A1 (fr) | 2005-03-04 | 2006-09-14 | Northwestern University | Epitopes angiogeniques de liaison a l'heparine, amphiphiles peptidiques, compositions auto-assemblees et procedes d'utilisation associes |
WO2006120019A2 (fr) * | 2005-05-13 | 2006-11-16 | Centre National De La Recherche Scientifique | Utilisation de nouveau codage genique pour nouvel element de la famille mcm2-8 dans les compositions pharmaceutiques |
MX2008000253A (es) | 2005-07-08 | 2008-04-02 | Biogen Idec Inc | Anticuerpos de sp35 y usos de los mismos. |
WO2007014338A2 (fr) * | 2005-07-26 | 2007-02-01 | Siemens Medical Solutions Diagnostics | Polymorphismes de nucleotides uniques a susceptibilite par rapport a une maladie cardio-vasculaire |
WO2007037601A1 (fr) * | 2005-09-28 | 2007-04-05 | Knu-Industry Cooperation Foundation | Polypeptide inhibant la transmigration de leucocytes ou la croissance et/ou la métastase de cellules cancéreuses, et une protéine de fusion de celui-ci |
EP1790664A1 (fr) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Anticorps monoclonaux contre claudin-18 pour le traitement du cancer |
DE602005023550D1 (de) | 2005-12-14 | 2010-10-21 | Licentia Ltd | Verwendungen eines neurotrophischen Faktors |
EP2044216A2 (fr) * | 2006-07-03 | 2009-04-08 | Exonhit Therapeutics SA | Produits de la transcription spécifiques de la prostate et leur utilisation pour des thérapeutiques et des diagnostics du cancer de la prostate |
EP2066810A2 (fr) * | 2006-09-08 | 2009-06-10 | Corixa Corporation | Procédés, compositions, et kits de détection et de surveillance d'un cancer du colon |
US8076295B2 (en) | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
US8999634B2 (en) * | 2007-04-27 | 2015-04-07 | Quest Diagnostics Investments Incorporated | Nucleic acid detection combining amplification with fragmentation |
GB0805159D0 (en) | 2008-03-19 | 2008-04-23 | Sancho Madrid David | Immune modulation via C-type lectin |
ES2553270T3 (es) * | 2007-07-27 | 2015-12-07 | Immatics Biotechnologies Gmbh | Nuevo epítopo inmunogénico para inmunoterapia |
US7863021B2 (en) | 2007-09-05 | 2011-01-04 | Celera Corporation | Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof |
WO2009034661A1 (fr) * | 2007-09-12 | 2009-03-19 | Toppan Printing Co., Ltd. | Procédé de diagnostic et induction d'une résistance à un virus |
ES2401233T3 (es) | 2007-10-17 | 2013-04-18 | Universidad de Córdoba | Isoformas del receptor tipo 5 de somatostatina humana producidas por tratamiento alternativo y pares de oligonucleótidos para la detección de las mismas por PCR |
HUE024903T2 (en) | 2007-12-26 | 2016-02-29 | Xencor Inc | FC variants with modified binding to FCRN |
GB0803352D0 (en) * | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
ES2584438T3 (es) | 2008-03-21 | 2016-09-27 | Universiteit Hasselt | Biomarcadores para artritis reumatoide |
EP2315779A2 (fr) | 2008-07-09 | 2011-05-04 | Biogen Idec MA Inc. | Compositions comprenant des anticorps anti-lingo ou leurs fragments |
ATE531383T1 (de) | 2008-07-24 | 2011-11-15 | Nsgene As | Therapeutische verwendung eines wachstumsfaktors, metrnl |
ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
CA2758687A1 (fr) | 2008-11-14 | 2010-05-20 | Gen-Probe Incorporated | Compositions, kits et procedes pour la detection d'acide nucleique de campylobacter |
WO2010062960A2 (fr) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | Méthodes de détermination d'une réceptivité à une thérapie par anti-tnfα lors d’une maladie intestinale inflammatoire |
WO2010066018A1 (fr) * | 2008-12-09 | 2010-06-17 | Alethia Biotherapeutics Inc. | Nouveau variant rétroviral endogène humain d’erv3 et utilisations de celui-ci pour diagnostiquer le cancer des ovaires |
WO2010120830A1 (fr) | 2009-04-13 | 2010-10-21 | Northwestern University | Nouvelles structures peptidiques pour la régénération des cartilages et procédés pour les utiliser |
WO2011028952A1 (fr) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes |
ES2802623T3 (es) | 2010-01-27 | 2021-01-20 | Massachusetts Inst Technology | Agentes polipeptídicos técnicamente diseñados para la neutralización dirigida de amplio espectro de la gripe |
AU2011312417B2 (en) | 2010-09-29 | 2015-08-20 | Agensys, Inc. | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins |
WO2012041328A1 (fr) | 2010-10-01 | 2012-04-05 | Nsgene A/S | Traitement de l'allodynie, de l'hyperalgésie, de la douleur spontanée et de la douleur illusionnelle |
DK2651430T3 (en) * | 2010-12-14 | 2018-08-27 | Hananja Ehf | Biological activity of placental protein 13 |
US9474786B2 (en) | 2011-09-05 | 2016-10-25 | Nsgene A/S | Treatment of allodynia |
WO2013068445A1 (fr) * | 2011-11-09 | 2013-05-16 | Sanofi | Diacylglycérol lipase et applications associées |
PT3489254T (pt) | 2012-04-30 | 2022-12-30 | Biocon Ltd | Proteínas de fusão direcionadas/imunomoduladoras e seus métodos de fabrico |
WO2013167153A1 (fr) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Anticorps utiles dans le diagnostic du cancer |
CN104470541A (zh) | 2012-05-14 | 2015-03-25 | 比奥根艾迪克Ma公司 | 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂 |
WO2013174404A1 (fr) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer |
CN105073776B (zh) | 2012-11-13 | 2019-04-12 | 拜恩科技股份公司 | 用于治疗表达紧密连接蛋白的癌症疾病的制剂 |
WO2014127785A1 (fr) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer |
US9023353B2 (en) * | 2013-03-13 | 2015-05-05 | The Board Of Trustees Of The University Of Arkansas | Anti-(+)—methamphetamine monoclonal antibodies |
WO2014146672A1 (fr) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer |
CA2908553A1 (fr) | 2013-03-27 | 2014-10-02 | Cedars-Sinai Medical Center | Attenuation ou regression de la fibrose et de l'inflammation par inhibition de la fonction tl1a et des voies de signalisation connexes |
JP7019233B2 (ja) | 2013-07-11 | 2022-02-15 | モデルナティエックス インコーポレイテッド | CRISPR関連タンパク質をコードする合成ポリヌクレオチドおよび合成sgRNAを含む組成物ならびに使用方法 |
WO2015010108A1 (fr) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature de la voie de signalisation de tl1a (tnfsf15) |
JP6915987B2 (ja) | 2013-09-25 | 2021-08-11 | シトムクス セラピューティクス,インコーポレイティド | マトリックスメタロプロテイナーゼ基質及び他の切断可能部分並びにそれらの使用方法 |
CA2925658C (fr) | 2013-10-01 | 2022-12-06 | Mie University | Antigene contenant une sequence d'interepitope favorisant la presentation d'antigene aux cellules t |
IL302642A (en) | 2014-01-31 | 2023-07-01 | Cytomx Therapeutics Inc | Polypeptide substrates that activate matriptase and U-plasminogen and other cleavable groups, preparations containing them and their uses |
JP2018504400A (ja) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Lingo‐1拮抗薬及び脱髄障害の治療のための使用 |
MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
EP3307070A4 (fr) * | 2015-06-12 | 2019-01-02 | Emory University | Compositions de croissance et de survie pour des cellules capables de produire des anticorps et procédés associés |
CN108138198B (zh) * | 2015-09-04 | 2022-10-28 | 合成基因组股份有限公司 | 为提高的产率而改造的微生物 |
KR20180127416A (ko) | 2016-03-17 | 2018-11-28 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
US20200330606A1 (en) * | 2016-03-29 | 2020-10-22 | Valkyrie Therapeutics Inc. | Modulation of structural maintenance of chromosome-1 expression |
US9611297B1 (en) | 2016-08-26 | 2017-04-04 | Thrasos Therapeutics Inc. | Compositions and methods for the treatment of cast nephropathy and related conditions |
US11125757B2 (en) | 2017-05-26 | 2021-09-21 | Emory University | Methods of culturing and characterizing antibody secreting cells |
EP3508499A1 (fr) | 2018-01-08 | 2019-07-10 | iOmx Therapeutics AG | Anticorps ciblant et d'autres modulateurs d'un gène d'immunoglobuline associé à une résistance contre des réponses immunitaires antitumorales et leurs utilisations |
AU2020261435A1 (en) * | 2019-04-26 | 2021-11-25 | Sangamo Therapeutics, Inc. | Engineering AAV |
JP2022538688A (ja) | 2019-07-05 | 2022-09-05 | イオックス セラピューティクス アーゲー | IGSF11(VSIG3)のIgC2に結合する抗体及びその使用 |
WO2021083958A1 (fr) * | 2019-10-29 | 2021-05-06 | Specialites Pet Food | Nouveaux peptides induisant la satiété |
EP4149952A1 (fr) * | 2020-05-12 | 2023-03-22 | Institut Curie | Épitopes néo-antigéniques associés à des mutations sf3b1 |
WO2022008027A1 (fr) | 2020-07-06 | 2022-01-13 | Iomx Therapeutics Ag | Anticorps de liaison à l'igv d'igsf11 (vsig3) et leurs utilisations |
CN117529492A (zh) * | 2021-01-21 | 2024-02-06 | 鹿特丹伊拉斯谟大学医疗中心 | 用于治疗的t细胞 |
US20220260597A1 (en) * | 2021-02-18 | 2022-08-18 | Beren Therapeutics P.B.C. | Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins |
WO2023225602A1 (fr) * | 2022-05-20 | 2023-11-23 | Medikine, Inc. | Polypeptides de liaison au récepteur de l'interleukine-18 et leurs utilisations |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4446240A (en) * | 1981-01-30 | 1984-05-01 | Nerenberg Samuel T | Pancreas specific protein systems |
US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
US6080540A (en) * | 1990-04-20 | 2000-06-27 | Cold Spring Harbor Laboratory | Cloning of mammalian genes in microbial organisms and methods for pharmacological screening |
JP2845623B2 (ja) * | 1990-11-26 | 1999-01-13 | アメリカ合衆国 | 細胞のストレス転写因子 |
US5721352A (en) * | 1991-02-19 | 1998-02-24 | University Of Florida Research Foundation | Entomopoxvirus expression system |
US5840870A (en) * | 1995-12-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Polynucleotides PANC1A and PANC1B associated with pancreatic cancer |
WO1999014234A2 (fr) * | 1997-09-17 | 1999-03-25 | Genentech, Inc. | Stimulation ou inhibition de l'angiogenese et de la cardiovascularisation |
US5912160A (en) * | 1995-08-22 | 1999-06-15 | Thomas Jefferson University | Gab1, Grb2 binding protein, and compositions for making and methods of using the same |
JP3462313B2 (ja) * | 1995-08-24 | 2003-11-05 | キッコーマン株式会社 | 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体dna及び変異型ウリカーゼの製造法 |
US5998165A (en) * | 1995-12-29 | 1999-12-07 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a protein associated with pancreatic cancer |
JP2000511410A (ja) * | 1996-04-29 | 2000-09-05 | ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | ナンセンス介在rna崩壊の哺乳動物の調節因子 |
US6500934B1 (en) * | 1996-07-24 | 2002-12-31 | Michael Rush Lerner | Bivalent agonists for G-protein coupled receptors |
US5976834A (en) * | 1997-01-09 | 1999-11-02 | Smithkline Beecham Corporation | cDNA clone HNFJD15 that encodes a novel human 7-transmembrane receptor |
US5925521A (en) * | 1997-03-31 | 1999-07-20 | Incyte Pharmaceuticals, Inc. | Human serine carboxypeptidase |
CA2232743A1 (fr) * | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | Tl5, homologue tnf |
WO1998045435A2 (fr) * | 1997-04-10 | 1998-10-15 | Genetics Institute, Inc. | MARQUEURS SECRETES DE SEQUENCE EXPRIMEE (sEST) |
IT1291110B1 (it) * | 1997-04-15 | 1998-12-29 | Istituto Europ Di Oncologia S | Interattori intracellulari e specificita' di legame del dominio eh |
US5948641A (en) * | 1997-05-29 | 1999-09-07 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a metal response element binding protein |
WO1998055620A1 (fr) * | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Element ntn-2 de la famille des ligands du tnf |
US5932442A (en) * | 1997-09-23 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Human regulatory molecules |
US5972660A (en) * | 1997-10-22 | 1999-10-26 | Incyte Pharmaceuticals, Inc. | Human hydroxypyruvate reductase |
DE19818598A1 (de) * | 1998-04-19 | 1999-10-21 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Pankreasnormalgewebe |
CA2327317A1 (fr) * | 1998-04-29 | 1999-11-04 | Genesis Research And Development Corporation Limited | Polynucleotides isoles de cellules de la peau et leurs procedes d'utilisation |
US6262249B1 (en) * | 1998-06-23 | 2001-07-17 | Chiron Corporation | Pancreatic cancer genes |
CA2296792A1 (fr) * | 1999-02-26 | 2000-08-26 | Genset S.A. | Sequences marqueurs exprimees et proteines humaines codees |
-
2001
- 2001-01-17 WO PCT/US2001/001351 patent/WO2001055355A1/fr active Search and Examination
- 2001-01-17 AU AU2001241409A patent/AU2001241409A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001340 patent/WO2001055321A2/fr active Search and Examination
- 2001-01-17 CA CA002395666A patent/CA2395666A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001309 patent/WO2001055308A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001333 patent/WO2001055448A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001348 patent/WO2001055368A1/fr active Search and Examination
- 2001-01-17 CA CA002395729A patent/CA2395729A1/fr active Pending
- 2001-01-17 WO PCT/US2001/001343 patent/WO2001055323A2/fr active Search and Examination
- 2001-01-17 CA CA002395699A patent/CA2395699A1/fr active Pending
- 2001-01-17 WO PCT/US2001/001355 patent/WO2001055207A1/fr not_active Application Discontinuation
- 2001-01-17 CA CA002394039A patent/CA2394039A1/fr not_active Abandoned
- 2001-01-17 WO PCT/US2001/001322 patent/WO2001055343A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001327 patent/WO2001055203A1/fr active Search and Examination
- 2001-01-17 AU AU2001250770A patent/AU2001250770A1/en not_active Abandoned
- 2001-01-17 CA CA002395827A patent/CA2395827A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001312 patent/WO2001054733A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001314 patent/WO2001055310A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001326 patent/WO2001055315A2/fr active Search and Examination
- 2001-01-17 CA CA002395734A patent/CA2395734A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001316 patent/WO2001054473A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001325 patent/WO2001055202A1/fr active Search and Examination
- 2001-01-17 CA CA002398877A patent/CA2398877A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001241418A patent/AU2001241418A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001359 patent/WO2001055328A2/fr active Application Filing
- 2001-01-17 CA CA002392438A patent/CA2392438A1/fr not_active Abandoned
- 2001-01-17 AU AU2001241414A patent/AU2001241414A1/en not_active Abandoned
- 2001-01-17 CA CA002395787A patent/CA2395787A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001241412A patent/AU2001241412A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001301 patent/WO2001055303A2/fr not_active Application Discontinuation
- 2001-01-17 CA CA002397407A patent/CA2397407A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001241416A patent/AU2001241416A1/en not_active Abandoned
- 2001-01-17 CA CA002393912A patent/CA2393912A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001302 patent/WO2001055304A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001240 patent/WO2001055302A2/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001353 patent/WO2001055206A1/fr not_active Application Discontinuation
- 2001-01-17 CA CA002395403A patent/CA2395403A1/fr not_active Withdrawn
- 2001-01-17 CA CA002395654A patent/CA2395654A1/fr not_active Withdrawn
- 2001-01-17 CA CA002395885A patent/CA2395885A1/fr not_active Withdrawn
- 2001-01-17 CA CA002398411A patent/CA2398411A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001352 patent/WO2001055327A2/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001356 patent/WO2001055173A2/fr not_active Application Discontinuation
- 2001-01-17 CA CA002395849A patent/CA2395849A1/fr active Pending
- 2001-01-17 WO PCT/US2001/001349 patent/WO2001054474A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001338 patent/WO2001055367A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001335 patent/WO2001055319A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001344 patent/WO2001055324A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001315 patent/WO2001055311A2/fr active Search and Examination
- 2001-01-17 AU AU2001241415A patent/AU2001241415A1/en not_active Abandoned
- 2001-01-17 CA CA002395872A patent/CA2395872A1/fr not_active Withdrawn
- 2001-01-17 CA CA002395693A patent/CA2395693A1/fr active Pending
- 2001-01-17 WO PCT/US2001/001317 patent/WO2001055201A1/fr active Search and Examination
- 2001-01-17 CA CA002392751A patent/CA2392751A1/fr not_active Abandoned
- 2001-01-17 WO PCT/US2001/001306 patent/WO2001055307A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001336 patent/WO2001055204A1/fr active Search and Examination
- 2001-01-17 CA CA002395858A patent/CA2395858A1/fr not_active Withdrawn
- 2001-01-17 CA CA002393652A patent/CA2393652A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001241408A patent/AU2001241408A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001313 patent/WO2001055200A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001332 patent/WO2001055318A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001357 patent/WO2001055208A1/fr not_active Application Discontinuation
- 2001-01-17 AU AU2001241417A patent/AU2001241417A1/en not_active Abandoned
- 2001-01-17 CA CA002392398A patent/CA2392398A1/fr not_active Abandoned
- 2001-01-17 CA CA002397839A patent/CA2397839A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001342 patent/WO2001059064A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001311 patent/WO2001055309A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001358 patent/WO2001055163A1/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001330 patent/WO2001055447A1/fr active Search and Examination
- 2001-01-17 CA CA002395295A patent/CA2395295A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001354 patent/WO2001057182A2/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001310 patent/WO2001055387A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001321 patent/WO2001055312A2/fr active Search and Examination
- 2001-01-17 CA CA002395671A patent/CA2395671A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001308 patent/WO2001055364A2/fr active Search and Examination
- 2001-01-17 CA CA002395738A patent/CA2395738A1/fr not_active Withdrawn
- 2001-01-17 CA CA002393618A patent/CA2393618A1/fr not_active Abandoned
- 2001-01-17 CA CA002392428A patent/CA2392428A1/fr not_active Abandoned
- 2001-01-17 AU AU2001241405A patent/AU2001241405A1/en not_active Abandoned
- 2001-01-17 CA CA002395398A patent/CA2395398A1/fr not_active Withdrawn
- 2001-01-17 CA CA002395178A patent/CA2395178A1/fr not_active Withdrawn
- 2001-01-17 CA CA002392422A patent/CA2392422A1/fr not_active Abandoned
- 2001-01-17 CA CA002392450A patent/CA2392450A1/fr not_active Abandoned
- 2001-01-17 CA CA002395724A patent/CA2395724A1/fr active Pending
- 2001-01-17 WO PCT/US2001/001341 patent/WO2001055322A2/fr active Search and Examination
- 2001-01-17 AU AU2001241413A patent/AU2001241413A1/en not_active Abandoned
- 2001-01-17 CA CA002393002A patent/CA2393002A1/fr not_active Withdrawn
- 2001-01-17 CA CA002394841A patent/CA2394841A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001239 patent/WO2001055301A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001328 patent/WO2001055316A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001350 patent/WO2001055350A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001324 patent/WO2001055314A2/fr active Search and Examination
- 2001-01-17 AU AU2001241407A patent/AU2001241407A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001337 patent/WO2001055205A1/fr active Search and Examination
- 2001-01-17 AU AU2001241410A patent/AU2001241410A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001345 patent/WO2001055325A2/fr active Search and Examination
- 2001-01-17 CA CA002392757A patent/CA2392757A1/fr not_active Abandoned
- 2001-01-17 CA CA002395816A patent/CA2395816A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001241406A patent/AU2001241406A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001339 patent/WO2001055320A2/fr not_active Application Discontinuation
- 2001-02-05 AU AU4313701A patent/AU4313701A/xx active Pending
- 2001-02-08 AU AU4141101A patent/AU4141101A/xx active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2395403A1 (fr) | Acides nucleiques, proteines et anticorps | |
US20050197285A1 (en) | Human secreted proteins | |
US20060223090A1 (en) | Polynucleotides encoding human secreted proteins | |
EP1381622A2 (fr) | Proteines secretees par les humains | |
US20070055056A1 (en) | 251 human secreted proteins | |
US20050176061A1 (en) | Human secreted proteins | |
CA2395811A1 (fr) | Acides nucleiques, proteines, et anticorps | |
CA2395838A1 (fr) | Acides nucleiques, proteines et anticorps | |
US20070026454A1 (en) | Human secreted proteins | |
CA2399943A1 (fr) | Anticorps, polypeptides et polynucleotides afferents au systeme immunitaire | |
CA2394022A1 (fr) | Acides nucleiques, proteines et anticorps | |
CA2395889A1 (fr) | Acides nucleiques, proteines et anticorps | |
CA2446610A1 (fr) | 20 proteines humaines secretees | |
CA2393941A1 (fr) | Acides nucleiques, proteines et anticorps | |
CA2395857A1 (fr) | Acides nucleiques, proteines et anticorps | |
US20070015162A1 (en) | 99 human secreted proteins | |
CA2395815A1 (fr) | Acides nucleiques, proteines et anticorps | |
US20070032414A1 (en) | Human secreted proteins | |
CA2395794A1 (fr) | Acides nucleiques, proteines, et anticorps | |
CA2393954A1 (fr) | Acides nucleiques, proteines et anticorps |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AZWI | Withdrawn application |